Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Single-centre, Randomised, Double-blind, Double-dummy, Placebo Controlled, 4-way Crossover Phase I Study to Investigate the Effect of 2 Single Doses (400 microg and 1200 microg) of Inhaled AZD3199 on QT/QTc Interval, Compared to Placebo, Using Moxifloxacin (Avelox) as a Positive Control, in Healthy Male Volunteers.

Trial Profile

A Single-centre, Randomised, Double-blind, Double-dummy, Placebo Controlled, 4-way Crossover Phase I Study to Investigate the Effect of 2 Single Doses (400 microg and 1200 microg) of Inhaled AZD3199 on QT/QTc Interval, Compared to Placebo, Using Moxifloxacin (Avelox) as a Positive Control, in Healthy Male Volunteers.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 22 Feb 2011

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AZD 3199 (Primary) ; AZD 3199 (Primary) ; Moxifloxacin
  • Indications Acute exacerbations of chronic bronchitis; Acute sinusitis; Asthma; Bacterial infections; Chronic obstructive pulmonary disease; Community-acquired pneumonia; Intra-abdominal infections; Pelvic inflammatory disorders; Respiratory tract infections; Skin and soft tissue infections; Tuberculosis
  • Focus Pharmacodynamics
  • Most Recent Events

    • 23 Oct 2010 New trial record
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top